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Abstract 1
Abstract
The European Cancer Information System 
(ECIS) indicates that in the EU over 355,000 
women were diagnosed with breast cancer in 
2020 (13.3% of all cancer diagnoses).
Despite advances in early detection and 
better understanding of the molecular bases 
of breast cancer biology, approximately 30% 
of all patients with early-stage breast cancer 
have recurrent disease, which is metastatic in 
most cases.
To offer better treatment with increased efficacy 
and low toxicity, selecting therapies based 
on the patient and the clinical and molecular 
characteristics of the tumour is necessary.
Although preclinical breast cancer research 
relies heavily on animal models, experimental 
approaches that more accurately recapitulate 
breast cancer pathogenesis are still missing. 
Furthermore, in vivo models, mostly rodents, 
present some disadvantages: high costs; high-
variability (due to lack of standardisation 
across laboratories); and most importantly the 
physiological environment provided is not the 
human one.
Therefore, the JRC’s EU Reference Laboratory 
for alternatives to animal testing (EURL ECVAM) 
launched a study to survey the state of the 
art of human-based models for breast cancer 
described in the scientific literature from 
January 2014 to March 2019, by retrieving 
specific information from 935 selected peer-
reviewed publications.
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1  Introduction
Breast cancer is the most commonly diagnosed 
cancer among women worldwide. Although 
there have been several breakthroughs in the 
treatment of breast cancer in the past few 
decades, the high incidence of relapse and 
progression after conventional therapies is 
deeply concerning and indicates a great need 
for developing new therapeutics (Ju et al., 
2018).
1.1 Overview of breast cancer
Breast cancer is curable in about 70–80% 
of patients with early-stage, non-metastatic 
disease. Advanced breast cancer with distant 
organ metastases is considered incurable with 
currently available therapies. 
On the molecular level, breast cancer is a 
heterogeneous disease; molecular features 
include activation of human epidermal growth 
factor receptor 2 (HER2, encoded by ERBB2), 
activation of hormone receptors (oestrogen 
receptor and progesterone receptor) and/or 
BRCA mutations. Treatment strategies differ 
according to molecular subtype.
The impressive increase in knowledge in the 
field of molecular biology and immunology 
has helped to elucidate the molecular 
characteristics of cancer representing the 
basis for a plethora of upcoming drugs. 
However, although important improvements 
have been achieved in recent years in terms of 
metastatic breast cancer outcomes, more and 
better treatments are needed. Additionally, 
the mechanisms underlying tumour resistance 
and how to overcome it are main topics of 
ongoing research.
Knowing the driving pathway at every given 
moment will enable the correct determination 
of the optimal sequence of therapies, which 
currently is largely unknown for all advanced 
breast cancer subtypes. 
All existing therapies hit less than 500 molecular 
targets (Drews, 2000) suggesting that there 
are many unexplored targets for drug discovery 
within the human interactome that comprises 
possibly 1 million proteins and over 1 trillion 
potential interconnections. Nonetheless, 
there are clearly other limitations in drug 
development. Less than 10% of investigational 
drugs based on new molecules proceed beyond 
early development (Kola and Landis, 2004); the 
approval rate for new oncology drugs is about 
5% (Kinders et al., 2007).
Perhaps the lack of significant progress partly 
reflects the drug development process in which 
preclinical animal models play a central role. 
The leading causes of attrition of new drugs 
are generally cited as being unpredictable 
toxicities and lack of efficacy, the early 
identification of which are primary goals for 
preclinical animal models.
Furthermore, as breast cancer is a highly 
heterogeneous disease, heterogeneity is often 
evident even within the same tumour. Cell 
line xenografts and genetically manipulated 
mouse models are more homogeneous. The 
relative homogeneity of these models may 
Less than 10% of 
investigational drugs 
based on new molecules 
proceed beyond early 
development
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render them overpredictive or underpredictive, 
depending on how prevalent their phenotype 
is in the human disease. A prediction of 
high sensitivity often leads to a drug being 
considered a strong target for human testing.
Overpredicted drugs would show limited 
activity/potency in human efficacy trials and so 
(after significant investment) experience a high 
attrition rate if the animal models were too 
sensitive. While current breast cancer models 
may well overpredict sensitivity relative to 
the human disease, it is difficult to assess 
underprediction because the lack of activity in 
preclinical animal models could lead them to 
be dropped early. 
1.2 Recent development in 
breast cancer research
In recent years, great progress has been made 
in the molecular target therapy of breast 
cancer, representing the pioneering field of 
precision medicine. Trastuzumab is regarded 
as the cornerstone of targeted therapy in 
HER-2-positive breast cancer and shows 
considerable efficacy in both neoadjuvant and 
adjuvant therapy (Ross et al., 2009; Ishii et al., 
2019; Zimmer and Denduluri, 2019). 
CDK4/6 and mTOR inhibitors exhibit the ability 
to reverse the resistance to endocrine and 
targeted agents to some extent (Yardley et al., 
2013; Goel et al., 2017). PARP inhibitors also 
show immense potential in the treatment of 
the BRCA1/2-mutated subgroup (McCabe et 
al., 2006). Given that the hallmark of breast 
cancer is the great heterogeneity in which 
biomarkers are diverse not only between 
primary and metastatic tumours, but also 
within a single tumour or during tumour 
progression, in recent years surrogate intrinsic 
tumour phenotypes have also been used for 
treatment individualisation.
At research level, efforts continue for a better 
understanding of the biological heterogeneity 
of breast cancer, as well as of mechanisms of 
tumour resistance and biomarkers predictive of 
response to the different therapeutic options. 
The generation of primary cell lines from 
human tumour biopsy is highly informative to 
identify novel biomarkers for the development 
of personalised “antigen-specific antibody”. 
This approach overcomes the use of animal 
models for xenograft injection of commercial 
tumour cell lines, which partially resemble the 
real expression of breast cancer biomarkers. 
In addition, xenografts using human cell lines 
to test drug responses do not often correlate 
with clinical activity in patients. This is due to 
immunological deficits such as loss of T- and 
B-cell responses, depending on the selected 
mouse models (Richmond and Su, 2008). 
Moreover, the selection of cancer stem cells 
for in vitro cell culture from tumour biopsy 
and their protein and genetic characterisation 
is an exhaustive method to characterise each 
tumour population with the aim to develop 
specific therapy (Jin et al., 2017).
Recent studies reported the role of inflammation 
in the development of breast cancer, supporting 
the evidence that tumorigenic signalling 
pathways are not sufficient for explaining a 
complete breast tumour progression. In this 
The generation of primary 
cell lines from human tumour 
biopsy is highly informative 
to identify novel biomarkers 
for the development of 
personalised “antigen-specific 
antibody”
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contest also the role of the immune system 
is crucial. During the onset of breast cancer, 
immune system cells like lymphocytes, NK 
cells and macrophages produce inflammatory 
factors in the tumour microenvironment. Some 
of these factors are cytokines, like TNF-a, 
TGF-b, and interleukins, exerting a pivotal role 
in tumour progression and contributing to the 
induction of proliferation, angiogenesis and 
epithelial-mesenchymal transition (Bahiraee 
et al., 2019).
Breast cancer research is mostly carried 
out using animal models, which has been 
instrumentally useful so far since they 
can provide a physiologically relevant 
microenvironment and an intact immune 
system. From this perspective, many animal 
models have been generated. We can classify 
the in vivo models either as Genetic ally 
Engineered Mouse Models (GEMM, either 
conventional or conditionals), as Xenograft 
based (Cell-line Derived Xenograft, CDX; and 
Patient-Derived Xenografts, PDX) and as 
Syngeneic-transplant based (Park et al., 2018).
Although preclinical breast cancer research 
has relied until now on in vivo models, 
approaches that accurately recapitulate 
breast cancer pathogenesis are still missing 
(Manning et al., 2016). Furthermore, in vivo 
models also present certain disadvantages. In 
fact, in vivo murine models have: high costs; 
high-variability, due to lack of in vivo models 
standardisation across laboratories; and most 
importantly the physiological environment 
provided is the mouse microenvironment 
(Holen et al., 2017), not the human.
In order to explore the trends of human in 
vitro and in silico-based models in breast 
cancer research, we present here the results 
of the systematic literature review of 935 
scientific peer-reviewed articles, published 
from January 2014 to March 2019, using non-
animal methods in breast cancer research, 
retrieved in PubMed, Scopus and Web of 
Science databases.
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2 Methodology
The review strategy employed retrieved 
119,722 candidate abstracts. After a selection 
based on titles and abstracts, 48,327 scientific 
articles were retrieved for the full-text selection.
The full-text analysis resulted in a selection of 
935 articles, from which all the identified data 
were extracted and analysed.
2.1 Selection criteria
The systematic search strategy considered 
any scientific article describing or dealing with 
in vitro human models or methods or assays 
or test systems in the field of breast cancer 
research, based on the dynamic classification 
shown in Annex - Table 1, as inclusion criteria.
In addition, it was considered as inclusion 
criteria any scientific article describing or 
dealing with any in silico model, such as an 
algorithm or mathematical or computational 
simulations.
The following initial set of flagged search 
terms was determined as inclusion search 
terms, for the publications retrieval based on 
title/abstract analysis:
model* OR assay* OR “test* system*” OR “in 
vitro” OR “ex vivo” OR in-vitro OR ex-vivo OR 
organoid* OR spheroid* OR 3D OR coculture OR 
co-culture OR microfluidic* OR microphys* OR 
biops* OR explant* OR “cell culture” OR “stem 
cell*” OR stem-cell* OR “primary culture” OR 
simulation* OR algorithm* OR mathematic* OR 
computation* OR chip
The search strategy proposed considered the 
exclusion criteria listed in Annex - Table 2 
and the following initial set of flagged search 
terms were determined as exclusion search 
terms for the publications retrieval based on 
title/abstract analysis:
“mouse model” OR murine OR mice OR rat 
OR rats OR “Controlled Study” OR “Priority 
Journal” OR “Major Clinical Study” OR “Animal 
Experiment” OR “Animal Model” OR “Animal 
Tissue” OR “Prognosis” OR “Follow Up” OR 
“Follow-Up” OR “Retrospective Stud*” OR 
“Prospective Study” OR “Case Control Study” 
OR “case stud*” OR “case-stud*” OR “Nude 
Mouse” OR “Psychology” OR review OR “Case 
Report” OR questionnaire* OR “Diagnostic 
Imaging” OR “Mammography” OR cross-
sectional OR survey* OR “Meta-Analysis” 
OR “meta-analysis” OR hiv OR infection* OR 
aids OR hepatitis OR influenza OR “clinical 
trial*” OR xenotransplant* OR xenograft* OR 
papilloma* OR gvhd OR “qualitative study” 
OR workshop OR sympos* OR “conference* 
proceeding*” OR cohort OR descent OR ancestr* 
OR participant* OR population OR gwas OR 
“genome wide analysis” OR “methyl* analys*” 
OR polymorphism*
2.2 Information sources
To perform the systematic literature search, 
it was agreed to focus on human-based 
models published in the last five years 
(January 2014 up to March 2019). In order 
to generate the most inclusive datasets, 
multidisciplinary citation databases and 
indexing services (Web of Science and Scopus) 
and the specific biomedical sciences citation 
database, PubMed, were used. Furthermore, 
grey literature sources of information were 
monitored to retrieve news and/or highlights 
on non-animal methods in the field (Annex - 
Table 3).
2.3 Systematic search
We finally retrieved 935 full-texts from 
where the data were extracted and analysed. 
However, to end with the selected full-texts, 
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we applied five sequential strategies (Annex - 
Table 4) as illustrated in Figure 1.
We initially retrieved a total number of 119,722 
scientific peer-reviewed journal articles by 
applying Strategy A. After the selection based 
on titles and abstracts applying Strategies B 
and C, we finally sorted out 48,327 publications 
for full text review. During the analysis of the 
48,327 publications, we observed a significant 
risk of redundancy for few models, especially 
for immortalised cell lines. We managed 
to partially override such redundancy by 
designing a new strategy applied to abstracts 
(strategy D).
However, such high-represented models are 
still over represented in the repository due 
1 https://europa.eu/!bM83pv
to lack of their specific description in the 
abstract texts. We therefore designed a new 
strategy (strategy E) to specifically retrieve 
peer-reviewed publications reporting new 
models, lowering redundancy of high literature 
represented models.
2.4 Method summary
The data from the scientific articles were 
extracted based on the method-summary 
format including fields that are reported in 
Annex - Table 5. The resulting collection of 
advanced non-animal models is publicly 
available from the EURL ECVAM collection in 
the JRC Data Catalogue1.
Figure 1: Selection process.
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3 Results and discussion
3.1 Publications employing 
human-based models
After retrieving a total of 119,722 abstracts 
following our study criteria (see Section 1), 
we have selected and analysed 935 peer-
reviewed articles published from January 
2014 to March 2019. The vast majority of 
articles (924) dealt specifically with breast 
cancer and only 11 articles were focused 
on the role of inflammation in breast cancer 
research (Figure 2). The number of journal 
articles published increased each year and, 
in 2018, 214 publications reported the use 
of non-animal models compared to the 129 
articles of 2014 (Figure 2) which is the 66% 
more within 4 years.
The majority of peer-reviewed articles focused 
on breast cancer initiation and development 
(384 articles; Figure 3), including paramount 
processes like epithelial–mesenchymal 
transition, cancer stem cell (CSC) formation, 
metastatic behaviour or mutation functional 
significance (Mylona et al., 2014; Feng et al., 
2015; Avivar-Valderas et al., 2018; Bocci et 
Figure 2: Distribution of peer-reviewed articles by year of publication from January 2014 to March 2019. Articles 
are classified for their main focus: BC, Breast cancer; IBC, inflammatory breast cancer; or both IBC/BC.
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al., 2019). A total of 210 scientific articles 
employed non-animal models to develop 
and test pharmacological and/or physical 
treatment to stop or revert breast cancer 
pathogenesis (Figure 3), such as small 
molecules characterisation and testing and 
large-scale high-content screening based on 
advanced culture systems (Härmä et al., 2014; 
Li et al., 2016). Moreover, microenvironment-
tumour interactions were studied in 75 
publications (Figure 3), also using lab-on-chip 
technologies (Choi et al., 2015; 2016).
Forty-nine articles used non-animal models to 
study metastasis, reporting the development of 
new cell substrates able to prompt invasion and 
migration mimicking in vivo conditions (Cavo 
et al., 2018). A total of 36 articles focused on 
studying metastasis microenvironment, also 
presenting new models potentially scalable 
to high-throughput (Nagaraju et al., 2018) 
or describing specific players in the tumour-
stroma interaction (Hohensee et al., 2017). 
Non-animal models were also employed in 28 
publications to dissect breast cancer initiation 
and development with the aim of testing 
pharmacological and/or physical treatment 
(Figure 3), e.g. to evaluate photodynamic 
therapy (Yang et al., 2015), or chemical 
drug efficiency to inhibit stem/progenitor 
proliferation (Farnie et al., 2014).
Furthermore human-based models were 
used in 30 publications for tumour detection 
and classification for clinical stratification 
purposes, including emerging methods such as 
circulating tumour cells analysis (Hainsworth 
et al., 2016) or in silico prediction models 
Figure 3: Number of peer-reviewed publications focused on one or more breast cancer disease features. E.g.: 
384 publications out of 430 were focused on breast cancer initiation and development only, the remaining 46 
publications were focused on breast cancer initiation and development plus other disease features.
Results and discussion 13
(Karapanagiotis et al., 2018). The remaining 
studies were tackling many other aspects of 
breast cancer pathogenesis and therapeutic 
strategies (Figure 3).
3.2 Fields of application of 
advanced models: from 
cancer pathogenesis to 
drug discovery
In our analysis we identified eight areas of 
application of non-animal models in breast 
cancer research. They are listed in Figure 4.
 More than half of the publications focused on 
certain aspects of breast cancer pathogenesis 
to identify or to model specific disease 
mechanisms (51.2%; Figure 4A). This area 
showed an annual increase in the number of 
publications, which reached 108 articles in 
2018 (Figure 4B). A total of 29.5% of journal 
articles reported the use of advanced models 
in studies on drug development and testing of 
their efficacy against breast cancer (Figure 4A), 
using chemical libraries and not-directed to a 
specific target (Chen et al., 2018) or directed to 
specific cellular players (Patidar et al., 2016). 
During the 5-year period under analysis, the 
interest in using non-animal models for drug 
development in breast cancer increased 
overtime, almost doubling the number of 
publications (36 articles in 2014 vs. 70 in 
2018; Figure 4B). Publications reporting the 
development in breast cancer research of 
new models, such as new cell lines (Ali et al., 
2017), or new techniques, represented 10.9% 
of all the retrieved articles (Figure 4A), with 14 
articles published in 2018 and a median of 21 
articles from 2015 to 2018 (Figure 4B). 
A remaining 8.3% of publications dealt with 
the theoretical development of non-animal 
models including models aiming to predict cell 
survival to therapy (2.7%), both physical (Sung 
et al., 2018) and chemical (Lucantoni et al., 
2018), breast cancer diagnostic applications 
Figure 4: Eight applications for non-animal models in breast cancer research were identified. Panel A shows the 
percentage of each reported application in all retrieved articles, including publications from 2019. Panel B shows 
the distribution of articles by model application in breast cancer research from January 2014 to December 2018. 
The number of articles per year for the three major applications are shown.
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(2.0%), development of disease therapies 
(2.0%), qualification for specific applications 
(1.3%) (Figure 4A). Finally, 3 articles (0.3%) 
described their development both theoretically 
and experimentally.
3.3 Distribution of models into 
categories
The analysis of the scientific literature found 
that on the one hand 91% out of 935 selected 
publications used in vitro models for breast 
cancer research (Figure 5A), with a clear trend 
increasing overtime (Figure 5B). On the other 
hand, only a 5% were in silico models (Figure 
5A). Thirty-eight articles (4%) dealt with 
models integrating in silico and in vitro (Figure 
5A). The publication of articles presenting such 
in vitro/in silico models increased from the 
average of 5 articles per year to 15 articles in 
2018 (Figure 5B). Whereas the use of in silico 
models alone were reported in a maximum of 
12 publications in 2017 to a minimum of 6 
articles in 2018 (Figure 5B).
The in silico models reported in 49 articles were 
mainly computational models and algorithms 
for cancer initiation and development studies 
and for tumour detection and classification 
(Figure 5C) (Greenbaum et al., 2014; Chapa 
et al., 2016). Thirty-eight publications using 
both in vitro and in silico methods were 
mainly integrating breast cancer cell lines-
based models in combination with an in 
silico model (31 articles, Figure 5D). These 
Figure 5: Panel A shows the percentage for each model category in all retrieved 935 articles. Panel B shows the 
distribution of peer-reviewed articles by year of publication from January 2014 to March 2019. Panel C shows the 
number of peer-reviewed publication for each type of in silico model/method. Panel D shows the number of peer-
reviewed publications reporting the use of both in vitro and in silico human-based models.
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publications were mainly focused on breast 
cancer initiation and development (17 articles) 
and also on pharmacological and physical 
treatment of breast cancer cells (14 articles). 
Those studies that combine machine learning 
and in vitro approaches to identify new marker 
for evaluation in risk assessment (Ren et al., 
2018) or those developing mathematical 
model to study tumour evolution (Reiter et al., 
2018) are of particular interest.
Focusing on breast cancer research, in vitro 
studies from 2014 to 2018 used mainly cell-
based models with a constant increase year 
after year (Figure 6A), representing 84% of 
total retrieved articles (Figure 6B). The use 
of human ex vivo models was reported in 
107 peer-reviewed scientific articles during 
the period under analysis (Figure 6A), which 
corresponds to 12% of the total in vitro 
models we analysed (Figure 6B). Most ex vivo 
models were patient biopsies (88 articles), 
mainly solid biopsies used for the identification 
of biomarkers (Vici et al., 2014) or clinical 
applications, e.g. immunotherapy (Chen et 
al., 2019), while liquid biopsies were less 
represented (Bingham et al., 2017; Zhong et 
al., 2018) (Figure 6C). 
Organ slice, intended as explanted tumour cut 
to be used for in vitro studies (Carranza-Torres 
et al., 2015), were reported in 15 publications 
(Figure 6C).
Figure 6: From January 2014 to March 2019, a total of 891 publications were reporting the using of in vitro 
models in breast cancer research. Panel A shows the distribution of peer-reviewed articles by year of publication 
from January 2014 to March 2019 and by type of in vitro model; values for the three most reported categories are 
shown per each year. Panel B shows the percentage for each category with respect to total in vitro models. Panel C 
shows the number of peer-reviewed articles per each type of ex vivo model.
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The use of both cellular and ex vivo models in 
the same study represents another research 
approach (Chi et al., 2017), with 2% of 
publications reporting this strategy to address 
their research hypothesis (Figure 6A and B). 
Cell free approaches alone or in combination 
with cells were used in few cases (2.1% in 
total), representing a small niche of in vitro 
models, but including a large spectrum of 
disease areas spanning from the mutational 
landscape (Kirkizlar et al., 2015) to the 
development of immunosensors (Eletxigerra 
et al., 2016) (Figure 6A and B).
A total of 801 out of 935 publications dealt with 
cellular in vitro models. Due the importance of 
this category, we disaggregated the data to 
provide a better view of cellular models in use. 
In 82% of the publications using human cell-
based models, immortalised breast cancer 
cell lines were employed (Figure 7A). A total 
of 10% of the publications reported the use 
of immortalised cell lines and stem cell-like 
in vitro models and a 5% of research articles 
reported the use of human primary cultures 
(Figure 7A). Twenty-two articles (3%) reported 
the use in combination of immortalised cells 
and primary cell culture, while 8 articles (1%) 
Figure 7: From January 2014 to March 2019, a total of 801 publications reported the use of immortalised cell lines 
in breast cancer research. Panel A shows the percentage for each type of human cell-based models category with 
respect to total number of cellular models. Panel B shows the distribution of peer-reviewed articles dealing with 
different type of human cell based-models by year of publication from January 2014 to March 2019; values for 
the three most reported cell-based models category are shown per each year. Each bubble, in panel C, represents 
a human immortalised cell line. The area of each bubble is proportional to the number of publications employing 
the specific immortalised cell line, the 12 most abundant human immortalised cell lines are indicated with the 
corresponding absolute number of references.
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used as experimental paradigms multiple 
cellular models (Figure 7A). 
Immortalised cell lines reporting in journal 
articles increased from 87 publications in 
2014 to 156 in 2018 (Figure 7B). Whereas, 
the number of publications using immortalised 
cells and stem cell-like models increased, 
during the same period, more than three times 
from 7 to 23 research articles (Figure 7B). On 
the other hand, research articles reporting 
primary cell culture showed relatively constant 
rate of publications in our 5-year analysis 
(Figure 7B).
Regarding breast cancer immortalised cells, 
we observed hundreds of different cell lines 
employed in several experimental paradigms 
(Figure 7C). Breast cancer cells lines included 
cells derived by different sources and cells 
genetically modified from original cell lines 
with similar genomic background. The most 
common cell lines reported in peer-reviewed 
publications from January 2014 to March 
2019 were in order of frequency of use: MCF-
7; MDA-MB-231; T-47D; SKBR3; MCF 10A; BT-
474; MDA-MB-468; BT-549; ZR-75-1; Hs 578T; 
MDA-MB453; SUM149; SUM159 (Figure 7C).
3.4 Increased use of 3D 
models
Culture conditions are very important to 
understand whether disease modelling is able 
to mimic as much as possible the physiological 
microenvironment of breast cancer. A better 
modelling of physiological conditions enhances 
the reliability of in vitro results.
A total of 83.2% (655 articles) of all 
publications employing cell-based models, 
reported cell cultures of individual 
immortalised cell populations and stem cell-
like and primary cells (Figure 8). Only 9.6% (77 
articles) of the published studies employed co-
Figure 8: Type of human cell-based model by culturing conditions.
Advanced Non-animal Models in Biomedical Research: Breast Cancer18
culture systems, e.g. to study chemotaxis of 
metastatic cells or to model the crosstalk with 
tumour microenvironment (Chung et al., 2017; 
Daubriac et al., 2018), and 3% (24 articles) of 
articles reported the use of microphysiological 
systems (MPS), mostly microfluidics culture 
models for 3D (Sabhachandani et al., 2016) 
and 2D (Ren et al., 2018) applications (Figure 
8). The remaining 4.2% of studies (33 articles) 
employed several cell-based systems and 
culture conditions. 
Less than half of the individual cell populations 
were cultivated in 2D (347 articles) and 
33.2% were cultivated in 3D conditions (266 
articles; Figure 8), where the use of scaffolds 
(63 articles) was the main approach, e.g. for 
the study of matrix topography (Riching et al., 
2014; Clay et al., 2016) or microenvironment 
and metastasis (Eslami Amirabadi et al., 
2017), followed by organoids (15 articles), 
including patient-derived organoids (Shirure 
et al., 2018) and spheroids (15 articles), also 
used in microfluidic systems (Xia et al., 2017).
In 7.4% of studies it is reported the use of 
both 2D and 3D models (59 articles; Figure 
8), eventually comparing the two models or 
to highlight the value of their complementary 
use (Breslin and O’Driscoll, 2016; Yildiz-Ozturk 
et al., 2017). Moreover 9.7% of publications 
reported extracellular matrix-embedded 
conditions (2.5D) for individual cell cultures 
(78 articles; Figure 8). On the other hand, 
cellular co-culture models were almost equally 
used in 2D and 3D culture systems, while MPS 
were mainly used in 3D conditions and a minor 
fraction in 2D (Figure 8). A total of 39 articles 
(4.9%) reported the use of two individual cell 
populations cultivated both in 2.5D and 3D 
conditions (Figure 8).
The analysis of data collected showed that 3D 
models increased over time and, in 2018, they 
equaled the number of publications reporting 
2 Throughput is defined as the number of samples that can be processed in parallel.
3 Content is defined as the quantity of information retrieved by each sample with a single analysis or method.
2D model implementation (Figure 9A). A small 
increase in the use of multiple models in the 
same research article has been observed, from 
2014 to 2018, especially in 3D conditions 
(Figure 9A). 
Spheroids, formed by single cell population 
or in co-culture with other cells, were the 
most employed 3D models (278 articles), 
followed by the use of scaffolds (Figure 9B). 
Of note, the use of spheroids and scaffolds in 
microfluidic systems was also reported in 41 
peer-reviewed publications.
3.5 Relevance of advanced 
models for the disease 
features under analysis
Of all retrieved publications reporting 
non-animal models 22.4% focused on 
pharmacological and physical treatments of 
breast cancer and 41% studied the breast 
cancer initiation and development mechanisms 
(Figure 3).
To analyse these features, the throughput2 
(productivity or automatisation) and the content 
analysis are key to screen several treatments 
in many different models and to retrieve as 
much molecular signalling information as 
possible. Hence, we screened the articles to 
determine the level of throughput and content 
of analysis3 and we found that 770 articles 
described low-throughput use of models, 112 
articles a medium-throughput level and 50 
articles a high-throughput usage (Figure 10).
From a content perspective, 835 studies 
applied low content analysis methods, 
whereas 83 were reporting high-content 
analysis (Figure 10). This resulted in 73.6% of 
articles reporting both low-throughput use and 
low-content analysis (Figure 10). On the one 
hand, 4.1% of the publications reported high-
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Figure 9: Distribution of articles by year of publication and by culture dimension. A total of 188 articles reported 
the use of multiple models with different culture dimensions. Each dot represents a peer-reviewed publication.
throughput use of non-animal models, but low 
content analysis. On the other hand, 7.3% of 
publications employed high content methods 
of analysis, but low throughput (Figure 10). 
Only 1.1% of the publications employed 
human-based models in high-throughput and 
applying high-content methods of analysis 
(Figure 10).
To understand whether non-animal models 
were relevant to study a specific disease 
feature, we analysed each article taking into 
consideration the type of human-based model 
used to address a disease feature (Figure 
11). Seventy-nine percent of all retrieved 
publications implemented cellular models, 
where 36.6% were used to study breast 
cancer initiation and development and 21% 
were employed to test pharmacological and 
physical treatments (Figure 11). Cell-based 
models were also the main models to study 
metastatic processes and microenvironment-
tumour interactions, representing 7.8% and 
6.8% of all studies, respectively (Figure 11). 
In the 4.3% of all peer-reviewed publications, 
ex vivo models were employed to study breast 
cancer initiation and development (Figure 11).
Then, we analysed the relevance of each 
human-based model with respect to the target 
disease feature under consideration. We found 
630 peer-reviewed publications where the 
models had direct relevance for the disease 
feature that was studied (Figure 12). On the one 
hand, direct relevance was observed in 28.3% 
of the articles studying breast cancer initiation 
and development, 17.3% of the articles dealt 
with pharmacological or physical treatment, 
6,4% focused on metastasis and 6,4% focused 
on microenvironment-tumour interactions. 
2.7% of total publications were having a direct 
relevance for their use in tumour detection and 
classification (Figure 12). On the other hand, 
we determined that 258 scientific articles 
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Figure 10: Number of articles by their throughput and analysis of content level.
Figure 11: Number of articles and their distribution by the type of model used to address specific breast cancer 
features. Only percentage greater than 1% of the total retrieved peer-reviewed publications are shown.
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employed non-animal models in a supportive 
manner for the specific disease feature they 
addressed (Figure 12). This was assessed 
in 14.4% of the total retrieved publications 
for studying breast cancer initiation and 
development, 6.8% of the articles to test 
pharmacological or physical treatments, while 
4% of the publications dealt with metastasis 
and microenvironment-tumour interactions 
(2.4% and 1.6% respectively) (Figure 12). We 
were not able to determine the relevance of 
47 publications, correspondong to 5% of the 
total publications, mostly dealing with cancer 
initiation and development (Figure 12).
Figure 12: Number of articles and their distribution by the relevance for the use of non-animal modelNAMs in 
studying specific breast cancer features.
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4 Conclusions
The European Cancer Information System 
(ECIS) indicates that in the EU over 355,000 
women were diagnosed with breast cancer 
in 2020 (13.3% of all cancer diagnoses). 
Although 5% to 10% of breast cancer are likely 
hereditary, this high incidence highlights the 
lack of knowledge about the events triggering 
breast cancer initiation and whether it skips 
immunological recognition. 
This systematic review of human-based 
models for breast cancer resulted in 935 
articles using in vitro and/or in silico models 
to study 18 different aspects of breast cancer 
pathogenesis. The main disease features 
addressed were breast cancer initiation and 
development at cellular levels by using mainly 
immortalised cell lines in particular, and ex 
vivo models such as tumour biopsies. The 
main interest in breast cancer initiation and 
development among the research community 
mirror the great importance in discovering the 
molecular bases of the starting events.
The incidence of female breast cancer increased 
steadily from 1970 to 2016 (WHO 2020) and 
the biomedical research also has increased its 
efforts. Our 5 year-time analysis captured a 
similar trend with peer-reviewed publications, 
with the use of non-animal models increasing 
each year. In parallel we also observed an 
increase in their usage for drug development 
and testing, which indicates the importance of 
finding new and more effective treatments for 
breast cancer. On the other hand, the publication 
of new human-based models for breast cancer 
research was steady. However, the use of 3D 
models has increased suggesting a better 
approximation to breast cancer physiology, 
especially through the use of spheroids. 
Our analysis showed that the implementation 
of human-based in silico models in breast 
cancer research is still a minor niche, but 
applied to all disease features. It is also worth 
pointing out the small group of publications 
reporting the use of both in vitro and in silico 
models, which has great potential.
Human breast cancer immortalised cells end 
up being the undisputable most used model 
reported in the systematic review. In fact, 
hundreds of cell lines have been found as 
reported in 747 peer-reviewed publications, 
including genetic engineered lines derived from 
commercially available or already qualified 
cell lines. They have been employed to study 
breast cancer initiation, treatments, metastatic 
process and the microenvironment-tumour 
interactions using several culturing conditions.
 Regarding the selection of immortalised cell 
lines for modelling metastatic breast cancer 
an insightful evaluation has been made by 
an integrative analysis of genomic data (Liu 
et al., 2019). However, as in previous studies, 
most publications reported a low-throughput 
and low-content analysis. This was interesting 
since most of the models were immortalised 
cell lines in relative standard culture conditions, 
which would have allowed process automation 
and the analysis through omics.
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Considering the overall results of the review, 
the main conclusions are the following:
The use of non-animal models in human 
breast cancer research is extensive, 
especially in relation to cell-based in vitro 
models.
The human-based models are mostly 
applied to elucidate disease mechanisms 
and to test drug candidates. In particular, 
human-based models are focused on studying 
breast cancer initiation and development and 
on pharmacological or physical treatments.
Qualified and commercially available 
human breast cancer immortalised cell 
lines represent the most common models. 
In vitro immortalised cells are often 
cultured in 3D conditions, such as 
spheroids, to better mimic breast cancer 
pathophysiology.
Two-thirds of publications employed non-
animal model as a relevant model to study 
the disease features of interest in breast 
cancer research.
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Table 1: Inclusion criteria used to retrieve scientific articles from literature.
1. Cells cultures and/or co-cultures in 2D, 2.5D, 3D or Microphysiological Systems (MPS)
a. Primary cell cultures
b. Immortalised cell lines
c. Stem cells (SCs)
i. Pluripotent SCs
• Induced pluripotent SCs (iPSCs)
• Embryonic SCs (ESCs)
ii. Multipotent SCs
• Somatic SCs
• Fetal SCs
2. Ex vivo material
a. Biopsies
b. Organotypic cultures
c. Stem cells (SCs)
i. Explants
ii. Whole organ or organ slice
3. Cell-free assays
a. Biochemical assays
4. Gene reporting assays
5. In silico
a. Algorithm
b. Mathematical
c. Computational
d. Simulations
6 Annex
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1. The study does not deal with breast cancer
2. Secondary literature (review, meeting abstract, etc.)
3. Duplicate
4. No in vitro or in silico model or method
5. In vivo study
6. Test method not able to measure endpoints
7. The study does not focus on development/characterization of a valuable alternative test method/model
8. No information on applications
9. The study does not provide mechanistic/pathophysiological or biological relevance
10. No biomedical research application
11. No valuable non-animal model or method
12. Not English articles
13. Retracted Publication
14. Published before 2014
Table 2: Exclusion criteria used to retrieve scientific articles from literature.
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Multidisciplinary citation databases and indexing services
Web of Science http://webofknowledge.com/WOS
Scopus http://www.scopus.com/ 
Google Scholar http://scholar.google.com/ 
Biomedical sciences citation databases
PubMed http://www.ncbi.nlm.nih.gov/pubmed 
Foundations
American Breast Cancer Foundation http://www.abcf.org/
Breast Cancer Research Foundation http://www.bcrf.org/
Breastcancer.org http://www.breastcancer.org/
Societies
Breast Cancer – American Cancer Society https://cancer.org/cancer/breast-cancer.html
Eusoma http://www.Eusoma.org
Research institutions and programs
NIH – National Cancer Institute https://www.cancer.gov/types/breast/research
California Breast Cancer Research Program http://cbcrp.org
Three-dimensional breast cancer models for X-ray 
Imaging research – MaXIMA
https://maxima-tuv.eu/
Breast Cancer Research Program | Vanderbilt-Ingram 
Cancer Center
https://www.vicc.org/research/programs/breast
Westmead Breast Cancer Institute https://www.bci.org.au
Fred Hutch https://www.fredhutch.org/en/diseases/breast-cancer.
html
Charities
Breast Cancer Care https://www.breastcancercare.org.uk/
Breast Cancer Now – the UK’s largest breast cancer 
research charity
https://breastcancernow.org
Pink Ribbon Foundations www.pinkribbonfoundation.org.uk
Events
European Breast Cancer Conference (EBCC) www.ecco-org.eu/EBCC
Advanced Breast Cancer - 5th ESO-ESMO International 
Consensus Conference
http://www.abc-lisbon.org
IABCR 2019 – 31st International Association for Breast 
Cancer Research Conference
https://www.eacr.org/meeting/iabcr-2019-31st-
international-association-for-breast-cancer-research-
conference
4th Breast Cancer Congress www.breastanbul.org
10th Euro Breast Cancer Summit https://eurobreastcancer.cancersummit.org/2019
Melbourne International Breast Congress https://melbournebreast2018.org
Table 3: Information sources used for literature searches.
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Strategy Definition Presence rate1 Inclusion rate2 Pros & cons
A Bottom-Up
Wide-range strategy 
without any search 
term exclusion. This 
strategy retrieves 
a large amount of 
publications.
It should 
guarantee the 
highest presence 
rate among 
the bottom-up 
strategies.
Inclusion rate 
could be low.
A large amount of 
publications must be 
screened.
B
Bottom-Up + 
Scoring system
Wide-range strategy 
followed by a ranking 
system based on 
search terms scores.
Top rank should 
have the higher 
presence rate than 
the intermediate 
and low ranks.
This strategy 
should 
concentrate 
the eligible 
publications into 
the top rank 
(score >200).
Higher amount of 
publications than 
Strategy A; however 
the absolute number 
of publications could 
be lower.
C
Bottom-Up + 
Top-down + 
Scoring system
Wide-range strategy 
followed by a ranking 
system based on 
search terms scores. 
The exclusion terms 
are tailored by 
analysing eligible 
publications specific 
for each lot.
This strategy 
concentrated 
the eligible 
publications into a 
top-ranking class 
(score >200).
Top rank should 
have higher 
inclusion rate 
than Strategy C.
Higher publications 
than in Strategy A.
D Stand-by
The most represented 
redundant models are 
actively searched and 
shelved. 
Not applicable Not applicable
It avoids information 
dilution of new 
models, which are 
underrepresented. 
On the contrary, 
some applications 
of most represented 
models can be lost.
E Enrichment
Specific search terms 
for new models’ 
retrieval.
Not applicable Not applicable
It enriches the 
search with 
underrepresented 
models.
1 Presence rate: Percentage of pre-selected eligible publications existing inbuilt dataset for each lot.
2 Inclusion rate: Percentage of eligible publications selected by title and abstract analysis.
Table 4: Organisations relevant to respiratory disease modelling and non-animal methods.
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Field Definition Drop-down option
Model number
Model of breast cancer which is described 
in a paper
NA
Breast cancer type Type of breast cancer
BC (Breast Cancer) 
IBC (Inflammatory Breast Cancer) 
BC/IBC
Breast cancer subtype
Morphological, molecular and clinical 
characteristics investigated in the model
For example: 
BC (breast cancer) 
Claudin-low BC 
DCIS (Ductal Carcinoma in Situ) 
IBC (Inflammatory Breast Cancer) 
IDC (Invasive Ductal Carcinoma) 
IDC/ILC ((Invasive Ductal Carcinoma/
Invasive Lobular Carcinoma)
Disease features The disease feature studied by the model
For example: 
Cancer initiation and development 
Angiogenesis 
Metastasis 
Cancer landscape 
Drug discovery and/or testing
Category
The category of non-animal model assigned 
to the model
In vitro 
In silico 
In vitro/in silico
Type More specifications of the model category
Cells 
Cell-free 
Ex vivo 
Computational 
Algorithm 
Simulation 
Mathematical 
and their combinations
Cells Biological material source, if any
Immortalised 
Primary 
Stem cells 
n/a
Source Biological material source, if any
MCF-7 
MDA-MB-231 
fibroblasts and endothelial cells 
liquid biopsy
Cell culture type
If the model employs cells, this field 
specifies the tpe of cell culture
Culture 
Co-culture 
MPS (Microphysiological systems) 
and their combinations
Cel culture dimensions
If the model employs cells, this field 
specifies the dimensions of the cell culture
2D 
2.5D 
3D 
and their combinations
3D
If the model uses 3D cell cultures, this field 
specifies the type of the 3D dimension
Scaffolds 
Spheroids 
Organoid 
and their combinations
Table 5: Agreed categories for data extraction.
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Ex vivo
If the model is based on ex vivo cells/
tissues, this field specifies the type of 
materials
Biopsies 
Liquid biopsies 
Organ slice 
Whole organ 
and their combinations
Applications
Main scientific aim or application of the 
model
For example: 
Diagnosis of diseases 
Model/method development 
Diseases mechanism 
Drug development/testing
Biological endpoints
List of potential biological endpoints used 
in a model system to describe the disease 
mechanism and/or study focus
For example: 
Cytotoxicity 
Cell proliferation 
Invasion 
Metabolic activity
Throughput
Regarding productivity/automatisation of 
the model
High 
Medium 
Low
Potential
Possible multiple model application in 
addressing disease features
Yes (The method/model has future 
potential for its breast cancer 
applications). 
No (The method/model has no 
future potential for its breast cancer 
applications). 
n/a (not specified)
Relevance 
Biological relevance of the model for the 
disease feature in replacing animal models
Direct (The model is sufficient for the 
conclusions of the study). 
Supportive (The model is partially 
supporting the conclusions of the 
study). 
n/a (not specified)
DOI or link
Digital Object Identification number to 
retrieve the publication abstract. If not 
available, an alternative link is provided
-
 First author name
Name of the first author of the peer-
reviewed article
-
Year Publication year from 2014 to 2019 -
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